ClinicalTrials.gg
RecruitingNCT07416604ZEBRHA 2Updated Nov 3, 2026

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

A Phase 3 interventional study of NXT007 and Emicizumab in Hemophilia A, sponsored by Hoffmann-La Roche. Recruiting at 63 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 3, 2026First sites in Australia, Canada and IrelandSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies in Hemophilia A by Hoffmann-La Roche — 5 open to participants now, 8 under way, 4 of them phase 3. Hemophilia A · Hoffmann-La Roche.

Planned enrollment
Largest of 20
360 · median 58
Started
2026
with 3 others
Phase 3
12 of 25
3 open now
Registered
23rd of 25
by date

Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one has the largest planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 in phase 3, and was the 23rd registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

5 of the 25 studies in Hemophilia A by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hemophilia A by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia A of any severity (severe, moderate, and mild) with FVIII inhibitors.

03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of severe (FVIII:C \<1 International Unit per decilitre [IU/dL]) or moderate (FVIII:C between ≥1 IU/dL and ≤5 IU/dL) congenital hemophilia A with or without inhibitors against FVIII
  • Diagnosis of mild (FVIII:C between >5 IU/dL and \<40 IU/dL) congenital hemophilia A with chronic FVIII inhibitors, defined as documented FVIII inhibitor ( ≥0.6 BU/mL or ≥1.0 BU/mL only for laboratories with a historical sensitivity cutoff for inhibitor detection of 1.0 BU/mL) and chronic reduction of endogenous baseline FVIII:C to \<5 IU/dL for ≥12 months
  • Documented historical FVIII inhibitor assay results within the 12 months prior to enrollment
  • Documentation of the details of prophylactic and episodic FVIII treatment, bypassing agent (BPA) treatment, emicizumab prophylaxis treatment, and the number and type of bleeding episodes for at least the last 6 months prior to screening
  • For potential participants taking on-demand treatments prior to study entry: agreement to move to a prophylaxis treatment with either emicizumab or NXT007, according to assigned randomization

Exclusion criteria

Exclusion Criteria:

  • Sensitivity to any of the study investigations, or components thereof, or drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study
  • Use of systemic immunomodulators (e.g., interferon or rituximab) at the time of enrollment or planned use during the study, except for antiretroviral therapy to treat
  • Refusal to accept plasma-derived and/or blood product transfusion support in an emergency scenario
  • Planned surgery (excluding minor procedures, such as non-molar tooth extraction or incision and drainage) during the study
  • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease (e.g., severe left ventricular systolic dysfunction, left ventricular hypertrophy), coronary heart disease (symptomatic or with ischemia demonstrated by diagnostic testing)
  • History or presence of an abnormal that is deemed , (e.g., complete left bundle branch block, second- or third-degree atrioventricular heart block) or evidence or clinical history of prior myocardial infarction
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Main Study Treatment Period: NXT007 Prophylaxis

    Participants randomized to this arm will receive NXT007 prophylaxis for the main study treatment period.

    Combination Product: NXT007

  • Active comparator
    Main Study Treatment Period: Emicizumab Prophylaxis

    Participants randomized to this arm will receive emicizumab prophylaxis for the main study treatment period at 3 mg/kg once weekly (QW) for 4 weeks as loading doses, followed by maintenance dosing of either 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W). Loading doses are not required for participants who were taking emicizumab prior to study start.

    Drug: Emicizumab

  • Experimental
    Open-Label Extension Period: NXT007 Prophylaxis

    After the main study treatment period, participants in the NXT007 arm will be able to continue with NXT007 dosing, and participants in the Emicizumab arm will be able to switch to NXT007, in the open-label extension period.

    Combination Product: NXT007

Interventions

  • Combination productNXT007

    NXT007 will be administered subcutaneously (SC) using an integrated drug-device combination product.

    Also known as: Zemocimig, RO7589655, RG6512

  • Emicizumab will be administered subcutaneously (SC) using vial and syringe.

    Also known as: Hemlibra, RO5534262, RG6013

06

What researchers measure

Primary outcomes

  1. Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

Secondary outcomes

  1. ABR for All Bleeds Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  2. ABR for Treated Spontaneous Bleeds Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  3. ABR for Treated Joint Bleeds Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  4. Adjusted Mean Treatment Burden Domain Score in Comprehensive Assessment Tool of Challenges in Hemophilia (CATCH) Questionnaire - Adult Version at Month 8

    Time frame: Month 8

  5. ABR for Treated Target Joint Bleeds Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  6. Percentage of Participants with Zero Treated Bleeds Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  7. Number of Injections and Dose per Bleed of Coagulation Factors or Bypassing Agent Administered to Treat a Bleed Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  8. Annualized Injection Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  9. Annualized Consumption Rate of FVIII or Bypassing Agent Over the Main Study Treatment Period

    Time frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

  10. Mean Treatment Burden Domain Score in CATCH Questionnaire - Adolescent Version at Month 8

    Time frame: Month 8

  11. Change From Baseline in Preoccupation Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)

    Time frame: At prespecified timepoints from Baseline until Study Completion (approximately 3.5 years)

  12. Change From Baseline in Social Activity Impact Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)

    Time frame: At prespecified timepoints from Baseline until Study Completion (approximately 3.5 years)

  13. Change From Baseline in Recreational Activity Impact Domain Score of the CATCH Questionnaire (Adult and Adolescent Versions)

    Time frame: At prespecified timepoints from Baseline until Study Completion (approximately 3.5 years)

  14. Physical Impact Domain Score of the Treatment Administration Satisfaction Questionnaire (TASQ) at Specified Timepoints

    Time frame: At prespecified timepoints from Baseline to Month 4

  15. Incidence and Severity of Adverse Events, With Severity Determined According To National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE V5.0) Grading Scale

    Time frame: From Baseline until Study Completion (approximately 3.5 years)

  16. Incidence and Severity of Thromboembolic Events and Thrombotic Microangiopathy

    Time frame: From Baseline until Study Completion (approximately 3.5 years)

  17. Incidence and Severity of Injection-Site Reactions

    Time frame: From Baseline until Study Completion (approximately 3.5 years)

  18. Incidence of Adverse Events Leading to Discontinuation of Assigned Study Treatment

    Time frame: From Baseline until Study Completion (approximately 3.5 years)

  19. Incidence of Severe Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions

    Time frame: From Baseline until Study Completion (approximately 3.5 years)

  20. Plasma Concentration of NXT007

    Time frame: At prespecified timepoints from Baseline to Study Completion (approximately 3.5 years)

  21. Percentage of Participants With Anti-Drug Antibodies (ADAs) Against NXT007 at Baseline and During the Study

    Time frame: At prespecified timepoints from Baseline to Study Completion (approximately 3.5 years)

  22. Percentage of Participants With Neutralizing ADAs Against NXT007

    Time frame: At prespecified timepoints from Baseline to Study Completion (approximately 3.5 years)

07

Study locations

63 of 63 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2028, 22 months after the start.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 22 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 18, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Feb 29, 2028
CompletionEst.
Jan 29, 2032
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added — first sites in Australia, Canada and Ireland. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences · Tianjin, ChinaSuspended→Recruiting
  • Fujian Medical University Union Hospital · Fuzhou, ChinaSuspended→Recruiting
Show 21 added (4 United States, 3 Australia, 2 China, 2 Ireland, 2 Netherlands, 2 United Kingdom, 1 Canada, 1 France, 1 Italy, 1 New Zealand, 1 Brazil, 1 Germany)
  • University Of Miami Hospital · Miami, United States
  • University of Michigan - 1500 E Medical Center Dr · Ann Arbor, United States
  • M Health Fairview - Pediatric Specialty Clinic-Discovery · Minneapolis, United States
  • The University of Texas Health Science Center at San Antonio · San Antonio, United States
  • The Alfred Hospital · Melbourne, Australia
  • Royal Children's Hospital Melbourne - PIN · Parkville, Australia
  • London Health Sciences Centre · London, Canada
  • Peking Union Medical College Hospital - East Campus · Beijing, China
  • Fujian Medical University Union Hospital · Fuzhou, China
  • AP-HP - Hôpital universitaire Necker-Enfants malades · Paris, France
  • St James's Hospital · Dublin, Ireland
  • Azienda Ospedaliera Universitaria Federico II · Naples, Italy
  • Amsterdam UMC Location AMC- Meibergdreef 9 · Amsterdam, Netherlands
  • Universitair Medisch Centrum Groningen · Groningen, Netherlands
  • Wellington Hospital · Wellington, New Zealand
  • Royal Free Hospital - PPDS · London, United Kingdom
  • St Thomas' Hospital · London, United Kingdom
  • Royal Prince Alfred Hospital · Camperdown, Australia
  • Hemocentro Da UNICAMP · São Paulo, Brazil
  • Universitätsklinikum Hamburg-Eppendorf · Hamburg, Germany
  • Children?s Health Ireland at Crumlin · Dublin, Ireland
across 2 updates, Oct 6, 2026 – Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    4 sites added. Fujian Medical University Union Hospital is now Recruiting
    Show 4 added (1 Australia, 1 Brazil, 1 Germany, 1 Ireland)
    • Royal Prince Alfred Hospital · Camperdown, Australia
    • Hemocentro Da UNICAMP · São Paulo, Brazil
    • Universitätsklinikum Hamburg-Eppendorf · Hamburg, Germany
    • Children?s Health Ireland at Crumlin · Dublin, Ireland
    + 1 other change: verification date
  2. Oct 6, 2026
    17 sites added — first sites in Australia, Canada and Ireland. Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences is now Recruiting
    Show 17 added (4 United States, 2 Australia, 2 China, 2 Netherlands, 2 United Kingdom, 1 Canada, 1 France, 1 Ireland, 1 Italy, 1 New Zealand)
    • University Of Miami Hospital · Miami, United States
    • University of Michigan - 1500 E Medical Center Dr · Ann Arbor, United States
    • M Health Fairview - Pediatric Specialty Clinic-Discovery · Minneapolis, United States
    • The University of Texas Health Science Center at San Antonio · San Antonio, United States
    • The Alfred Hospital · Melbourne, Australia
    • Royal Children's Hospital Melbourne - PIN · Parkville, Australia
    • London Health Sciences Centre · London, Canada
    • Peking Union Medical College Hospital - East Campus · Beijing, China
    • Fujian Medical University Union Hospital · Fuzhou, China
    • AP-HP - Hôpital universitaire Necker-Enfants malades · Paris, France
    • St James's Hospital · Dublin, Ireland
    • Azienda Ospedaliera Universitaria Federico II · Naples, Italy
    • Amsterdam UMC Location AMC- Meibergdreef 9 · Amsterdam, Netherlands
    • Universitair Medisch Centrum Groningen · Groningen, Netherlands
    • Wellington Hospital · Wellington, New Zealand
    • Royal Free Hospital - PPDS · London, United Kingdom
    • St Thomas' Hospital · London, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07416604
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Apr 27, 2026
Primary completion
Feb 29, 2028 (estimated)
Completion
Jan 29, 2032 (estimated)
Last update
Nov 3, 2026

Study contacts

Reference Study ID Number: BO45887 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NXT007

Start the discussion